SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBNFree Report) by 20.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 196,968 shares of the company’s stock after selling 49,733 shares during the quarter. Principal Financial Group Inc. owned approximately 0.49% of SI-BONE worth $4,134,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. RiverPark Advisors LLC boosted its stake in SI-BONE by 22.6% during the 4th quarter. RiverPark Advisors LLC now owns 3,151 shares of the company’s stock worth $66,000 after purchasing an additional 580 shares during the last quarter. Amalgamated Bank boosted its stake in SI-BONE by 12.9% during the 4th quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock worth $123,000 after purchasing an additional 673 shares during the last quarter. Arizona State Retirement System boosted its stake in SI-BONE by 7.7% during the 4th quarter. Arizona State Retirement System now owns 10,675 shares of the company’s stock worth $224,000 after purchasing an additional 762 shares during the last quarter. Swiss National Bank boosted its stake in SI-BONE by 1.1% during the 3rd quarter. Swiss National Bank now owns 76,600 shares of the company’s stock worth $1,627,000 after purchasing an additional 800 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in SI-BONE by 14.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock worth $179,000 after purchasing an additional 1,106 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Stock Down 0.4 %

Shares of SIBN opened at $13.47 on Friday. The firm has a market cap of $555.10 million, a P/E ratio of -12.36 and a beta of 1.24. SI-BONE, Inc. has a 12-month low of $13.34 and a 12-month high of $29.51. The company’s 50-day moving average price is $14.97 and its 200 day moving average price is $17.69. The company has a current ratio of 9.76, a quick ratio of 8.75 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBNGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $37.87 million for the quarter, compared to analyst estimates of $36.45 million. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. On average, sell-side analysts forecast that SI-BONE, Inc. will post -0.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SIBN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 27th. Piper Sandler started coverage on SI-BONE in a report on Thursday, March 28th. They set an “overweight” rating and a $25.00 price target on the stock. Morgan Stanley reduced their price target on SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, May 7th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of SI-BONE in a report on Tuesday, May 7th. Finally, Truist Financial reiterated a “buy” rating and set a $24.00 price target (down previously from $26.00) on shares of SI-BONE in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $27.29.

Read Our Latest Report on SI-BONE

Insider Activity at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares in the company, valued at $3,175,222.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other SI-BONE news, Director Mika Nishimura sold 2,500 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $16.22, for a total transaction of $40,550.00. Following the sale, the director now directly owns 19,350 shares in the company, valued at $313,857. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Anshul Maheshwari sold 2,425 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now owns 205,516 shares in the company, valued at $3,175,222.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,868 shares of company stock worth $310,659. Company insiders own 5.40% of the company’s stock.

About SI-BONE

(Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Featured Articles

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBNFree Report).

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.